We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current 1TMO market cap is 199.26B. The company's latest EPS is USD 15.7054 and P/E is 35.07.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 25.96B | 32.22B | 39.21B | 44.92B | 42.86B |
| Operating Income | 4.59B | 7.79B | 10.03B | 8.39B | 6.86B |
| Net Income | 3.7B | 6.38B | 7.73B | 6.95B | 6B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 58.38B | 69.05B | 95.12B | 97.15B | 98.73B |
| Total Liabilities | 28.71B | 34.55B | 54.15B | 53.01B | 51.88B |
| Total Equity | 29.68B | 34.51B | 40.86B | 44.03B | 46.72B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 4.97B | 8.29B | 9.31B | 9.15B | 8.41B |
| Investing | -1.49B | -1.51B | -21.93B | -2.16B | -5.14B |
| Financing | -3.12B | 959M | 6.58B | -2.81B | -3.62B |
| Market Cap | 199.26B |
| Price to Earnings Ratio | 35.07 |
| Price to Sales Ratio | 4.91 |
| Price to Cash Ratio | 26.03 |
| Price to Book Ratio | 4.49 |
| Dividend Yield | - |
| Shares Outstanding | 381.72M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 19 |
| 52 Week Change | 13.55% |
| 52 Week High | 551.40 |
| 52 Week Low | 459.70 |
| Spread (Intraday) | 2.4 (0.46%) |
| Company Name | Thermo Fisher Scientific Inc |
| Address |
108 lakeland ave dover, delaware 19901 |
| Website | https://www.thermofisher.com |
| Industry | meas & controlling dev, nec (3829) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
